Using urine samples to diagnose disease in preterm newborns

NewsGuard 100/100 Score
Prof. Evgeny NikolaevTHOUGHT LEADERS SERIES...insight from the world’s leading experts

An interview with Professor Evgeny Nikolaev, conducted by April Cashin-Garbutt, MA (Cantab)

Which respiratory pathologies are preterm newborns at risk of, and how have these conditions traditionally been tested for?

The majority of patients in neonatal intensive care units are premature babies, who often have infectious (congenital pneumonia) or noninfectious (tachypnea, infant respiratory distress syndrome) respiratory pathologies.

Routine clinical and laboratory tests are not always good for fast and accurate identification of pathogens. Also, the invasiveness of examination and therapy methods is a serious problem for the intensive care and nursing of premature infants.

Evgeny Nikovaev Anna Bugrova Olga Kechko Alexey Kononikhin

Left to right - Head of team Prof. Evgeny Nikovaev, Anna Bugrova, Olga Kechko, senior fellow Alexey Kononikhin

Why is it important to determine whether an infection or a failure in the development process is the underlying cause of the illness?

Identifying the cause of respiratory pathologies in preterm infants and providing them with the adequate treatment is crucial for nursing them back to health.

In particular, it is important to differentiate between the infectious and the noninfectious respiratory disorders, since the former require antibiotic treatment.

What sparked your research into the possibility of using urine samples for diagnosis?

Urine is a desirable material for the study and diagnostics of diseases. The urinary proteome of adults has been studied for more than 30 years, but studies of the urinary proteome in pediatrics, especially in neonatology, are limited.

It is worth noting that, to the best of our knowledge the urine proteome during the first week of life of premature infants with respiratory pathologies of infectious and noninfectious origin was not yet investigated.

How much information can be gained from the urinary proteome?

Urine contains proteins that are readily detectable in all studied individuals (adults, children, infants), also known as the core urine proteome, and infant-specific and disease-specific proteins.

In order to further specify the defined infant-specific dataset, the proteins were compared with the urinary proteome of healthy adults (men and pregnant women).

Which techniques did you use to determine whether respiratory pathologies were infectious or noninfectious?

Here we apply liquid chromatography coupled with high accuracy mass spectrometry to study the urine proteome of preterm neonates with respiratory disorders of infectious (pneumonia) and noninfectious (apnea, transient tachypnea, respiratory distress syndrome) origins.

Label-free proteomic data was compared for preterm neonates with respiratory disorders against term healthy newborns (control) and healthy adults (men and women) with the aim of defining the urine proteins that are disease-specific.

Newborn baby hospital - Arnon Thongkonghan

Why have studies of the urinary proteome in pediatrics, and in particular neonatology, been limited in the past?

New technologies are currently being developed rapidly and implemented at the clinic, including its newly established labs.

The major setback for the research of that kind, promising as it may be, has to do with the ethical issues. Nevertheless, a few studies were performed, and potential biomarkers in the urine samples of infants were demonstrated for predicting such pathologies as obstructive nephropathy and necrotizing enterocolitis and for monitoring the development of the urinary system.

What impact do you think this research will have?

In our pilot study, we succeeded in defining the core urinary proteome and the proteins that are specific to infants and pathological conditions. We are pioneers in the noninvasive identification of urinary biomarkers diagnosing respiratory conditions in newborns. The results are optimistic and will serve as a platform to move forward in developing a method of monitoring conditions in newborns.

What are the next steps for your research?

Verification of our results requires further research with a bigger sampling group and the inclusion of additional comparison groups to assess the specificity and diagnostic value of the presented panel of proteins.

Where can readers find more information?

The findings have been published in the Journal of Proteomics.

About Professor Evgeny Nikolaev

Evgeny N. Nikolaev BIG IMAGEEvgeny N. Nikolaev graduated from the Moscow Institute of Physics and Technology (PhysTech) in 1971. He received his Ph.D. in chemical physics from PhysTech in 1974 and his Dr. Sc. in 1992 from the Institute of Chemical Physics, Russian Academy of Sciences (ICP RAS).

In 1968 he joined the ICP RAS, where he has spent the bulk of his career. Early on, he contributed to developing the SIMS and FAB techniques to investigate cluster formation in ion and neutral bombardment of ices.

Later in his career, he was involved in the development of a thin film technology for data storage devices and computer automation of experiments. Since 1981 he has been involved in FT ICR mass spectrometry. The first direct measurement of ³He/T mass difference by FT ICR was performed by his group in 1983.

His research interests include, but are not limited to, molecular chirality, supercomputer modelling of ion clouds behavior in mass spectrometer devices, classification and analysis of organic carbon natural storages, development and characterization of dynamically harmonized Penning traps for FT ICR MS, and proteomics of the human body at extreme conditions.

He is the recipient of the honorary issue of the International Journal of Mass Spectrometry (2012). The Bruker Daltonics company is producing FT ICR mass spectrometer “Solarix” with the measuring ion trap developed by Evgeny Nikolaev.

April Cashin-Garbutt

Written by

April Cashin-Garbutt

April graduated with a first-class honours degree in Natural Sciences from Pembroke College, University of Cambridge. During her time as Editor-in-Chief, News-Medical (2012-2017), she kickstarted the content production process and helped to grow the website readership to over 60 million visitors per year. Through interviewing global thought leaders in medicine and life sciences, including Nobel laureates, April developed a passion for neuroscience and now works at the Sainsbury Wellcome Centre for Neural Circuits and Behaviour, located within UCL.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cashin-Garbutt, April. (2018, August 23). Using urine samples to diagnose disease in preterm newborns. News-Medical. Retrieved on April 24, 2024 from https://www.news-medical.net/news/20161109/Using-urine-samples-to-diagnose-disease-in-preterm-newborns.aspx.

  • MLA

    Cashin-Garbutt, April. "Using urine samples to diagnose disease in preterm newborns". News-Medical. 24 April 2024. <https://www.news-medical.net/news/20161109/Using-urine-samples-to-diagnose-disease-in-preterm-newborns.aspx>.

  • Chicago

    Cashin-Garbutt, April. "Using urine samples to diagnose disease in preterm newborns". News-Medical. https://www.news-medical.net/news/20161109/Using-urine-samples-to-diagnose-disease-in-preterm-newborns.aspx. (accessed April 24, 2024).

  • Harvard

    Cashin-Garbutt, April. 2018. Using urine samples to diagnose disease in preterm newborns. News-Medical, viewed 24 April 2024, https://www.news-medical.net/news/20161109/Using-urine-samples-to-diagnose-disease-in-preterm-newborns.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis